These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31304514)

  • 1. Plasma galectin-3 as a biomarker for clinical staging of heart failure: a cross-sectional evaluation of 100 cases.
    Gocer H; Günday M; Ünal M
    Clin Ter; 2019; 170(4):e267-e271. PubMed ID: 31304514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure.
    Stoltze Gaborit F; Bosselmann H; Kistorp C; Iversen K; Kumler T; Gustafsson F; Goetze JP; Sölétormos G; Tønder N; Schou M
    BMC Cardiovasc Disord; 2016 May; 16():117. PubMed ID: 27246703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure.
    Gopal DM; Kommineni M; Ayalon N; Koelbl C; Ayalon R; Biolo A; Dember LM; Downing J; Siwik DA; Liang CS; Colucci WS
    J Am Heart Assoc; 2012 Oct; 1(5):e000760. PubMed ID: 23316284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galectin-3: a new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure.
    Hrynchyshyn N; Jourdain P; Desnos M; Diebold B; Funck F
    Arch Cardiovasc Dis; 2013 Oct; 106(10):541-6. PubMed ID: 24090952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galectin-3 in patients with chronic heart failure: association with oxidative stress, inflammation, renal dysfunction and prognosis.
    Medvedeva EA; Berezin II; Surkova EA; Yaranov DM; Shchukin YV
    Minerva Cardioangiol; 2016 Dec; 64(6):595-602. PubMed ID: 27119370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study.
    Lok DJ; Van Der Meer P; de la Porte PW; Lipsic E; Van Wijngaarden J; Hillege HL; van Veldhuisen DJ
    Clin Res Cardiol; 2010 May; 99(5):323-8. PubMed ID: 20130888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study.
    Motiwala SR; Szymonifka J; Belcher A; Weiner RB; Baggish AL; Sluss P; Gaggin HK; Bhardwaj A; Januzzi JL
    Eur J Heart Fail; 2013 Oct; 15(10):1157-63. PubMed ID: 23666680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galectin-3 is associated with severe heart failure and death: A hospital-based study in Chinese patients.
    Wang N; Dang M; Zhang W; Lei Y; Liu Z
    Scand J Immunol; 2020 May; 91(5):e12826. PubMed ID: 31514240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation.
    Coromilas E; Que-Xu EC; Moore D; Kato TS; Wu C; Ji R; Givens R; Jorde UP; Takayama H; Naka Y; George I; Mancini D; Schulze PC
    BMC Cardiovasc Disord; 2016 Jun; 16():138. PubMed ID: 27301475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases.
    Mueller T; Leitner I; Egger M; Haltmayer M; Dieplinger B
    Clin Chim Acta; 2015 May; 445():155-60. PubMed ID: 25850080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Galectin-3 in Patients with Acute Heart Failure: Preliminary Report on First Polish Experience.
    Sygitowicz G; Tomaniak M; Filipiak KJ; Kołtowski Ł; Sitkiewicz D
    Adv Clin Exp Med; 2016; 25(4):617-23. PubMed ID: 27629834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of Serial Measurements of Soluble Suppression of Tumorigenicity 2 and Galectin-3 in Ambulatory Patients With Chronic Heart Failure.
    Miller WL; Saenger AK; Grill DE; Slusser JP; Bayes-Genis A; Jaffe AS
    J Card Fail; 2016 Apr; 22(4):249-55. PubMed ID: 26277907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic significance of serum galectin-3 levels in heart failure with preserved ejection fraction.
    Polat V; Bozcali E; Uygun T; Opan S; Karakaya O
    Acta Cardiol; 2016 Apr; 71(2):191-7. PubMed ID: 27090041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and prognostic accuracy of galectin-3 and soluble ST2 for acute heart failure.
    Mueller T; Gegenhuber A; Leitner I; Poelz W; Haltmayer M; Dieplinger B
    Clin Chim Acta; 2016 Dec; 463():158-164. PubMed ID: 27983996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between galectin-3 levels and fragmented QRS (fQRS) in patients with heart failure with reduced left ventricular ejection fraction.
    Barman HA; Durmaz E; Atici A; Kahyaoglu S; Asoglu R; Sahin I; Ikitimur B
    Ann Noninvasive Electrocardiol; 2019 Nov; 24(6):e12671. PubMed ID: 31155816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galectin-3 and Arterial Stiffness in Patients with Heart Failure: A Pilot Study.
    Oikonomou E; Karlis D; Tsalamadris S; Siasos G; Chrysohoou C; Vogiatzi G; Dimitropoulos S; Charalambous G; Kouskouni E; Tousoulis D
    Curr Vasc Pharmacol; 2019; 17(4):396-400. PubMed ID: 29968538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galectin-3 in Children with Chronic Heart Failure with Normal and Reduced Ejection Fraction: Relationship to Disease Severity.
    Kotby AA; Youssef OI; Elmaraghy MO; El Sharkawy OS
    Pediatr Cardiol; 2017 Jan; 38(1):95-102. PubMed ID: 27833993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure.
    van Kimmenade RR; Januzzi JL; Ellinor PT; Sharma UC; Bakker JA; Low AF; Martinez A; Crijns HJ; MacRae CA; Menheere PP; Pinto YM
    J Am Coll Cardiol; 2006 Sep; 48(6):1217-24. PubMed ID: 16979009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galectin-3 testing: validity of a novel automated assay in heart failure patients with reduced ejection fraction.
    Gruson D; Mancini M; Ahn SA; Rousseau MF
    Clin Chim Acta; 2014 Feb; 429():189-93. PubMed ID: 24365381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Galectin-3 in Heart Failure: An Update of the Last 3 Years.
    Gehlken C; Suthahar N; Meijers WC; de Boer RA
    Heart Fail Clin; 2018 Jan; 14(1):75-92. PubMed ID: 29153203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.